Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2014-12-18 16:18:48
Reporting Period:
Filing Date:
Accepted Time:
2014-12-18 16:18:48
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1446847 Ironwood Pharmaceuticals Inc IRWD Pharmaceutical Preparations (2834) 043404176
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1478521 J Michael Higgins C/o Ironwood Pharmaceuticals, Inc.
301 Binney Street
Cambridge MA 02142
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class B Common Stock Acquisiton 2014-12-16 15,987 $2.94 315,987 No 4 M Direct
Class B Common Stock Disposition 2014-12-16 15,987 $14.01 300,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class B Common Stock Employee Stock Option (Right to Buy) Disposition 2014-12-16 15,987 $0.00 15,987 $2.94
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
34,013 2017-01-22 No 4 M Direct
  1. In order to effect the sale, these shares of Class B Common Stock were converted into shares of Class A Common Stock in accordance with the issuer's certificate of incorporation.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 to $14.09, inclusive. The reporting person udertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2007 for the first 36 months, and vested as to 4.5833% of the shares of Class B Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2011.